Stockscreener 앱 받기
14.31
8.26%
1.145
전일 마감가:
$13.17
열려 있는:
$13.5
하루 거래량:
4.61M
Relative Volume:
2.50
시가총액:
$1.88B
수익:
$260.11M
순이익/손실:
$60.64M
주가수익비율:
33.29
EPS:
0.43
순현금흐름:
$92.29M
1주 성능:
+12.89%
1개월 성능:
+25.63%
6개월 성능:
+73.67%
1년 성능:
+97.76%
1일 변동 폭
$13.50
$16.20
1주일 범위
$11.96
$16.20
52주 변동 폭
$6.55
$16.20
Aurinia Pharmaceuticals Inc Stock (AUPH) Company Profile
명칭
Aurinia Pharmaceuticals Inc
전화
250-744-2487
주소
#140, 14315 - 118 AVENUE, EDMONTON, BC
AUPH을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AUPH
Aurinia Pharmaceuticals Inc
|
14.31 | 1.73B | 260.11M | 60.64M | 92.29M | 0.43 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.69 | 109.22B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
629.03 | 67.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
422.96 | 57.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
830.90 | 50.87B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
182.67 | 39.72B | 447.02M | -1.18B | -868.57M | -6.1812 |
Aurinia Pharmaceuticals Inc Stock (AUPH) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-30 | 재개 | H.C. Wainwright | Buy |
| 2022-11-04 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2022-05-05 | 재개 | Cantor Fitzgerald | Overweight |
| 2021-12-10 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2021-10-28 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2021-01-25 | 재확인 | H.C. Wainwright | Buy |
| 2020-11-03 | 재확인 | H.C. Wainwright | Buy |
| 2020-06-17 | 개시 | BTIG Research | Buy |
| 2020-05-05 | 개시 | Cowen | Outperform |
| 2020-01-10 | 개시 | Jefferies | Buy |
| 2019-12-16 | 재확인 | H.C. Wainwright | Buy |
| 2018-03-16 | 재확인 | Cantor Fitzgerald | Overweight |
| 2018-02-08 | 개시 | RBC Capital Mkts | Outperform |
| 2017-10-30 | 재확인 | H.C. Wainwright | Buy |
| 2017-05-18 | 재확인 | H.C. Wainwright | Buy |
| 2017-04-11 | 개시 | Cantor Fitzgerald | Overweight |
| 2017-03-22 | 재확인 | FBR & Co. | Outperform |
| 2016-12-30 | 재확인 | H.C. Wainwright | Buy |
| 2016-08-17 | 재확인 | H.C. Wainwright | Buy |
| 2016-06-30 | 개시 | H.C. Wainwright | Buy |
| 2015-05-08 | 개시 | MLV & Co | Buy |
모두보기
Aurinia Pharmaceuticals Inc 주식(AUPH)의 최신 뉴스
Aurinia Pharmaceuticals Inc. Increases Revenue Guidance for the Year 2025 - MarketScreener
Aruinia stock gains after Q3 earnings beat (AUPH:NASDAQ) - Seeking Alpha
Aurinia Pharmaceuticals stock hits 52-week high at 13.6 USD - Investing.com
Aurinia Pharmaceuticals Boosts 2025 Sales Guidance Amid Strong Q3 Performance - TipRanks
Aurinia Pharmaceuticals Doubles Profit As Lupkynis Sales Jump - Finimize
Aurinia Pharmaceuticals (AUPH) Surpasses Q3 Earnings and Revenue Estimates - Yahoo Finance
Aurinia: Q3 Earnings Snapshot - News-Times
Aurinia Pharmaceuticals Inc $AUPH Shares Bought by Hussman Strategic Advisors Inc. - MarketBeat
Aurinia Pharmaceuticals Q3 profit doubles on strong LUPKYNIS sales, raises FY sales view - MarketScreener
Aurinia Pharmaceuticals Inc. SEC 10-Q Report - TradingView
Aurinia Pharmaceuticals Reports Financial Results for the Three and Nine Months Ended September 30, 2025 and Provides Update on Recent Business Progress - Bluefield Daily Telegraph
Why Aurinia Pharmaceuticals Inc. is moving today2025 Trading Recap & Daily Entry Point Trade Alerts - newser.com
Aurinia Pharmaceuticals to Report Financial Results for the Three and Nine Months Ended September 30, 2025 and Provide Update on Recent Business Progress on November 4, 2025 - BioSpace
Is Aurinia Pharmaceuticals Inc. stock positioned well for digital economyTrend Reversal & Safe Capital Growth Trade Ideas - newser.com
FDA CDER Head Janet Tidmarsh Removed Amid Aurinia Pharmaceuticals Lawsuit Alleging Misconduct - geneonline.com
FDA Official Quits As Aurinia Sues Over 'Personal Vendetta' - Law360
FDA’s top drug regulator sued by drug company, resigns amid conduct probe - The Hill
Aurinia Pharmaceuticals Reportedly Files Lawsuit Against US FDA Official - MarketScreener
US FDA's drug division chief resigns amid ethics concerns and lawsuit - Reuters
FDA’s Top Drug Regulator Resigns, Agency Cites Personal Conduct - Bloomberg.com
Strategies to average down on Aurinia Pharmaceuticals Inc.2025 Analyst Calls & Consistent Growth Equity Picks - newser.com
Will Aurinia Pharmaceuticals Inc. stock recover faster than marketGlobal Markets & Weekly Stock Breakout Alerts - newser.com
Aurinia Pharmaceuticals Inc expected to post earnings of 16 cents a shareEarnings Preview - TradingView
Key metrics from Aurinia Pharmaceuticals Inc.’s quarterly data2025 Bull vs Bear & Expert-Curated Trade Recommendations - newser.com
Wall Street Breakfast Podcast: FDA Executive Controversy (undefined:AUPH) - Seeking Alpha
Is Aurinia Pharmaceuticals Inc. building a consolidation baseJuly 2025 Snapshot & AI Powered Trade Plan Recommendations - newser.com
Aurinia Pharmaceuticals To Report Q3 Results, Provide Update On Recent Business Progress On November 4 - TradingView
Published on: 2025-11-03 05:10:28 - newser.com
Can Aurinia Pharmaceuticals Inc. stock reach $100 price targetRecession Risk & Low Drawdown Investment Ideas - newser.com
PRESS DIGEST-Wall Street JournalNovember 3 - facilitiesmanagement-now.com
Analyzing drawdowns of Aurinia Pharmaceuticals Inc. with statistical toolsWeekly Trend Summary & Long-Term Capital Growth Ideas - newser.com
Is Aurinia Pharmaceuticals Inc. reversing from oversold territoryMarket Movement Recap & Free Weekly Watchlist of Top Performers - newser.com
Using data models to predict Aurinia Pharmaceuticals Inc. stock movementDip Buying & Free Reliable Trade Execution Plans - newser.com
Combining price and volume data for Aurinia Pharmaceuticals Inc.Weekly Trading Summary & Daily Profit Focused Stock Screening - newser.com
F.D.A. Drug Unit Chief Resigns, and Is Sued by Drug Company - The New York Times
Top FDA official Tidmarsh resigns after comments on kidney drug, HHS probe - Seeking Alpha
FDA Turmoil Spills Over To Aurinia Pharma As Lawsuit Targets Ex-Drug Review Chief — Retail Traders Cry ‘Stock Manipulation’ - Stocktwits
Is Aurinia Pharmaceuticals Inc. (IKAP) stock undervalued historicallyMarket Growth Summary & Free High Return Stock Watch Alerts - newser.com
FDA Official Steps Down, Sued by DrugmakerWSJ - The Wall Street Journal
Will breakout in Aurinia Pharmaceuticals Inc. lead to full recoveryWeekly Earnings Recap & Free Expert Approved Momentum Trade Ideas - newser.com
What analysts say about Aurinia Pharmaceuticals Inc IKAP stockMACD Trading Signals & Double Digit Wealth Tips - earlytimes.in
Visualizing Aurinia Pharmaceuticals Inc. stock with heatmaps2025 Momentum Check & Safe Investment Capital Preservation Plans - newser.com
Chart overlay techniques for tracking Aurinia Pharmaceuticals Inc.Market Performance Summary & Community Consensus Picks - newser.com
Using R and stats models for Aurinia Pharmaceuticals Inc. forecastingProfit Target & Weekly Market Pulse Alerts - newser.com
Is There An Opportunity With Aurinia Pharmaceuticals Inc.'s (NASDAQ:AUPH) 49% Undervaluation? - 富途牛牛
Aurinia Pharmaceuticals Inc (AUPH) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Aurinia Pharmaceuticals Inc 주식 (AUPH) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| TANG KEVIN | Director |
Aug 05 '25 |
Buy |
11.68 |
200,000 |
2,336,000 |
11,329,500 |
| TANG KEVIN | Director |
Aug 04 '25 |
Buy |
11.34 |
100,000 |
1,134,000 |
11,129,500 |
| Keenan Greg | Chief Medical Officer |
Aug 01 '25 |
Sale |
10.50 |
20,000 |
210,000 |
133,484 |
| Keenan Greg | Chief Medical Officer |
Mar 07 '25 |
Sale |
8.23 |
8,305 |
68,350 |
153,484 |
| Greenleaf Peter | Chief Executive Officer |
Mar 03 '25 |
Sale |
8.00 |
195,593 |
1,564,744 |
1,953,892 |
| Greenleaf Peter | Chief Executive Officer |
Mar 04 '25 |
Sale |
7.92 |
164,947 |
1,306,380 |
1,788,945 |
| Keenan Greg | Chief Medical Officer |
Mar 03 '25 |
Sale |
8.00 |
12,239 |
97,912 |
161,789 |
| Miller Joseph M | Chief Financial Officer |
Mar 03 '25 |
Sale |
8.00 |
61,859 |
494,872 |
633,515 |
| Miller Joseph M | Chief Financial Officer |
Mar 04 '25 |
Sale |
7.92 |
56,154 |
444,740 |
577,361 |
| Robertson Stephen P. | EVP, General Counsel |
Mar 03 '25 |
Sale |
8.00 |
64,872 |
518,976 |
566,883 |
1.29%
0.56%
자본화:
|
볼륨(24시간):